---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023423"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:48:41.912191+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics Q2 2023 net loss $9.8M; clinical enrollment milestones; CFO appointed

## Summary
- Cash at June 30, 2023: $99.4M, down from $110.9M at Dec 31, 2022.
- Net loss Q2 2023: $9.83M vs $6.67M Q2 2022; operating expenses $7.79M up 18% YoY.
- Impairment charge of $2.99M on investment in Dynamic Cell Therapeutics (DCT).
- Phase 2 EVANGELINE PK cohort fully enrolled; Karisma-Endoxifen 70% enrolled; I-SPY 2 30% enrolled.
- Appointed Greg Weaver as CFO; US patent granted for enterically encapsulated endoxifen.

## SEC filing metadata
- accession: 0001437749-23-023423
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/0001437749-23-023423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/atos20230804_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023423
- JSON: https://secwatch.observer/filing/0001437749-23-023423.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023423.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $9,830.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss for the second quarter of 2023 was $9,830
  - Result: reported results
  source text: On August 14, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2023 financial results and a Company update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/0001437749-23-023423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.